# A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

Source: https://onco.cc/trials/nct04657991/  
OnCo record `nct04657991` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Encorafenib, Binimetinib, Pembrolizumab in melanoma, run by Pfizer, active and no longer recruiting.

## Summary

A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma is a phase 3 interventional study registered as NCT04657991 by Pfizer, with 257 participants enrolled, started 2021-01-15 and due to reach its primary completion in 2026-10-30. Interventions recorded: Encorafenib, Binimetinib, Pembrolizumab. Conditions listed: Melanoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04657991
- Phase: 3
- Setting: A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS PLACEBO PLUS PEMBROLIZUMAB IN PARTICIPANTS WITH BRAF V600E/K MUTATION-POSITIVE METASTATIC OR UNRESECTABLE LOCALLY ADVANCED MELANOMA
- Sponsor: Pfizer
- Enrolled: 257

## Sources

- ClinicalTrials.gov NCT04657991: https://clinicaltrials.gov/study/NCT04657991

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- drugs: [Binimetinib](https://onco.cc/drugs/binimetinib/), [Encorafenib](https://onco.cc/drugs/encorafenib/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Pfizer (incl. Seagen)](https://onco.cc/companies/pfizer/)

---
JSON: https://onco.cc/api/v1/entities/nct04657991.json